BG63692B1 - Производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин и метод за получаването им - Google Patents

Производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин и метод за получаването им

Info

Publication number
BG63692B1
BG63692B1 BG105884A BG10588401A BG63692B1 BG 63692 B1 BG63692 B1 BG 63692B1 BG 105884 A BG105884 A BG 105884A BG 10588401 A BG10588401 A BG 10588401A BG 63692 B1 BG63692 B1 BG 63692B1
Authority
BG
Bulgaria
Prior art keywords
tetrahydroquinoline
fluorophenyl
cyclopentyl
dimethyl
substituted
Prior art date
Application number
BG105884A
Other languages
English (en)
Inventor
Guenter Schmidt
Arndt Brandes
Rolf Angerbauer
Michael Loegers
Matthias Mueller-Gliemann
Carsten Schmeck
Klaus-Dieter Bremm
Hilmar Bischoff
Delf Schmidt
Joachim Schuhmacher
Henry Giera
Holger Paulsen
Paul Naab
Michael Conrad
Juergen Stoltefuss
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19627419A external-priority patent/DE19627419A1/de
Priority claimed from DE19707199A external-priority patent/DE19707199A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of BG63692B1 publication Critical patent/BG63692B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C225/18—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings the carbon skeleton containing also rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретението се отнася до нови производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин с обща формула@@в която значенията на заместителите са посочени в описанието. Те се използват като междинни продукти при синтеза на фармакологично активни циклоалканопиридини с обща формула@@в която значенията на заместителите са посочени в описанието.@
BG105884A 1996-07-08 2001-09-10 Производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин и метод за получаването им BG63692B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19627419A DE19627419A1 (de) 1996-07-08 1996-07-08 Cycloalkano-pyridine
DE19707199A DE19707199A1 (de) 1997-02-24 1997-02-24 Neues Verfahren zur Herstellung von Cycloalkanopyridinen

Publications (1)

Publication Number Publication Date
BG63692B1 true BG63692B1 (bg) 2002-09-30

Family

ID=26027303

Family Applications (4)

Application Number Title Priority Date Filing Date
BG105883D BG63661B2 (bg) 1996-07-08 1997-07-04 Производно на 3-амино-1-пропенон
BG101747A BG63691B1 (bg) 1996-07-08 1997-07-04 Циклоалканопиридини
BG105884A BG63692B2 (bg) 1996-07-08 1997-07-04 Производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин и метод за получаването им
BG105884A BG63692B1 (bg) 1996-07-08 2001-09-10 Производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин и метод за получаването им

Family Applications Before (3)

Application Number Title Priority Date Filing Date
BG105883D BG63661B2 (bg) 1996-07-08 1997-07-04 Производно на 3-амино-1-пропенон
BG101747A BG63691B1 (bg) 1996-07-08 1997-07-04 Циклоалканопиридини
BG105884A BG63692B2 (bg) 1996-07-08 1997-07-04 Производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин и метод за получаването им

Country Status (37)

Country Link
US (1) US6069148A (bg)
EP (1) EP0818448B8 (bg)
JP (1) JP4146531B2 (bg)
KR (1) KR100473299B1 (bg)
CN (1) CN1175574A (bg)
AR (1) AR007729A1 (bg)
AT (1) ATE254106T1 (bg)
AU (1) AU728136B2 (bg)
BG (4) BG63661B2 (bg)
BR (1) BR9703884A (bg)
CA (1) CA2209640C (bg)
CO (1) CO4890849A1 (bg)
CU (1) CU22771A3 (bg)
CZ (1) CZ292031B6 (bg)
DE (1) DE59710982D1 (bg)
DK (1) DK0818448T3 (bg)
DZ (1) DZ2261A1 (bg)
EE (1) EE04342B1 (bg)
ES (1) ES2210417T3 (bg)
HR (1) HRP970330B1 (bg)
HU (1) HUP9701169A3 (bg)
ID (1) ID20376A (bg)
IL (1) IL121236A (bg)
MA (1) MA24262A1 (bg)
MY (1) MY118207A (bg)
NO (1) NO308844B1 (bg)
NZ (1) NZ328261A (bg)
PE (1) PE96898A1 (bg)
PL (1) PL320952A1 (bg)
PT (1) PT818448E (bg)
RU (1) RU2194698C2 (bg)
SK (1) SK284213B6 (bg)
TN (1) TNSN97115A1 (bg)
TR (1) TR199700585A2 (bg)
TW (1) TW575566B (bg)
UA (1) UA52594C2 (bg)
YU (1) YU28997A (bg)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE19709125A1 (de) * 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
CN1338944A (zh) 1998-12-23 2002-03-06 G.D.瑟尔有限公司 用于心血管适应症的胆固醇酯转移蛋白抑制剂和苯氧异丁酸类衍生物的联合形式
EP1140184B1 (en) 1998-12-23 2003-06-04 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
KR20010102964A (ko) 1998-12-23 2001-11-17 윌리암스 로저 에이 심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US6458851B1 (en) 1998-12-23 2002-10-01 G. D. Searle, Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
BR9916484A (pt) 1998-12-23 2002-01-22 Searle Llc Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6683113B2 (en) * 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US6924313B1 (en) 1999-09-23 2005-08-02 Pfizer Inc. Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
BR0210518A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EA006777B1 (ru) 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Фармацевтические композиции адсорбатов аморфного лекарственного средства
DE10148436A1 (de) * 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
BR0213501A (pt) 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
FR2832919B1 (fr) 2001-12-04 2004-02-20 Imv Technologies Seringue d'injection du contenu d'une paillette pour l'insemination artificielle d'un animal ou le transfert embryonnaire
CA2470931A1 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003061604A2 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1474144B1 (en) * 2002-02-01 2008-08-06 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
MXPA04007438A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
KR20050110017A (ko) * 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
KR20060021870A (ko) 2003-05-30 2006-03-08 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의용도
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
MXPA06003357A (es) * 2003-09-26 2006-06-08 Japan Tobacco Inc Metodo para inhibir la produccion de lipoproteina remanente.
CA2537942A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
SI1689757T1 (sl) 2003-11-12 2015-01-30 Sino-Med International Alliance, Inc. Heterociklične spojine boronske kisline
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
MY139887A (en) 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7786163B2 (en) 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
RU2393151C2 (ru) * 2004-12-18 2010-06-27 Байер Шеринг Фарма Акциенгезельшафт 4-циклоалкилзамещенные производные тетрагидрохинолина и их применение в качестве лекарств
DE102004060997A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Chemische Verbindung und ihre Verwendung
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
FR2883000B1 (fr) * 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
EP2332526A3 (en) 2005-10-21 2011-10-12 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
WO2007054896A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
DE102006012548A1 (de) 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN101573340A (zh) 2006-11-01 2009-11-04 百时美施贵宝公司 糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途
EP2094692B1 (en) 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
US8309730B2 (en) 2007-11-01 2012-11-13 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor AP-1 and/or NF-kappab acitivity and use thereof
RU2010140442A (ru) * 2008-03-05 2012-04-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
JP2012522015A (ja) 2009-03-27 2012-09-20 ブリストル−マイヤーズ スクイブ カンパニー Ｄｐｐ−ｉｖ阻害剤を用いて主要有害心血管事象を予防する方法
BR112012016111B1 (pt) * 2010-01-04 2017-06-13 Nippon Soda Co composto heterocíclico contendo nitrogênio, e, fungicida agrícola
KR20130000379A (ko) * 2010-02-19 2013-01-02 베링거 인겔하임 인터내셔날 게엠베하 트리사이클릭 피리딘 유도체, 이러한 화합물을 함유하는 약제, 이의 용도 및 이의 제조방법
MX2013000359A (es) 2010-07-09 2013-02-11 Ube Industries Compuesto de piridina sustituida.
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
TWI570118B (zh) * 2012-01-06 2017-02-11 第一三共股份有限公司 經取代之吡啶化合物的酸加成鹽
WO2014039412A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
SG11202100417RA (en) 2018-07-19 2021-02-25 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen

Also Published As

Publication number Publication date
DK0818448T3 (da) 2004-03-22
CA2209640A1 (en) 1998-01-08
KR980009246A (ko) 1998-04-30
HRP970330B1 (en) 2004-06-30
NO308844B1 (no) 2000-11-06
EE04342B1 (et) 2004-08-16
SK284213B6 (en) 2004-11-03
CU22771A3 (es) 2002-07-24
TNSN97115A1 (en) 2005-03-15
JPH1067746A (ja) 1998-03-10
ATE254106T1 (de) 2003-11-15
CN1175574A (zh) 1998-03-11
CA2209640C (en) 2009-09-22
YU28997A (sh) 2000-03-21
BG63661B2 (bg) 2002-08-30
ID20376A (id) 1998-12-03
CO4890849A1 (es) 2000-02-28
NO973145L (no) 1998-01-09
PE96898A1 (es) 1999-02-13
NZ328261A (en) 1999-06-29
PL320952A1 (en) 1998-01-19
AU2845197A (en) 1998-01-15
AR007729A1 (es) 1999-11-10
BG63691B1 (bg) 2002-09-30
IL121236A0 (en) 1998-01-04
JP4146531B2 (ja) 2008-09-10
RU2194698C2 (ru) 2002-12-20
ES2210417T3 (es) 2004-07-01
SK92797A3 (en) 1998-01-14
US6069148A (en) 2000-05-30
EP0818448A1 (de) 1998-01-14
NO973145D0 (no) 1997-07-07
HUP9701169A3 (en) 1999-07-28
KR100473299B1 (ko) 2005-09-30
UA52594C2 (uk) 2003-01-15
EE9700145A (et) 1998-02-16
IL121236A (en) 2001-05-20
HUP9701169A2 (hu) 1999-06-28
AU728136B2 (en) 2001-01-04
HRP970330A2 (en) 1998-04-30
MA24262A1 (fr) 1998-04-01
DE59710982D1 (de) 2003-12-18
DZ2261A1 (fr) 2002-12-18
MY118207A (en) 2004-09-30
CZ214397A3 (cs) 1998-01-14
BG101747A (bg) 1998-04-30
TR199700585A2 (xx) 1998-01-21
BR9703884A (pt) 1998-09-01
CZ292031B6 (cs) 2003-07-16
PT818448E (pt) 2004-04-30
TW575566B (en) 2004-02-11
EP0818448B8 (de) 2004-03-17
BG63692B2 (bg) 2002-09-30
EP0818448B1 (de) 2003-11-12

Similar Documents

Publication Publication Date Title
BG63692B1 (bg) Производни на заместен 2-циклопентил-4-/4-флуорофенил/-7,7-диметил-тетрахидрохинолин и метод за получаването им
DE69830504D1 (de) Antithrombotische mitteln
HUP9701048A2 (hu) Új eljárás sildenafil előállítására és a felhasznált új köztitermékek
MX9702865A (es) Agentes estrogenicos.
ES2173480T3 (es) Preparacion de derivados de ciclohexeno carboxilato.
EA200000274A2 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
CY1110738T1 (el) Παραγωγα aminoαλκυλβενζοϋλ-βενζοφουραν ή βενζοθειοφαιν, μεθοδος παρασκευης τους και συνθεσεις που τα περιεχουν
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
AU1676200A (en) Polyhydroxylated heterocyclic derivatives as anti-coagulants
BR9508308A (pt) Derivados de benzoíla e sintese dos mesmos
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
ATE244699T1 (de) Substituierte anilinverbindungen
TR200200353T2 (tr) Torsemid Polimorfları
SE9804212D0 (sv) Compounds
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
DE69703115D1 (de) Zwischenprodukte um 2-imidazolin-5onederivate herzustellen.
EA200401099A1 (ru) Производные гетероциклического амида
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
EA200301133A1 (ru) Способ получения дифторбензилэпоксидов и промежуточные соединения
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas